Biomarkers and surrogate end points in clinical trials of tuberculosis treatment - Reply to Davies et al.

被引：0
|
作者：
Walzl, Gerhard
Mistry, Rohit
Dockrell, Hazel M.
van Helden, Paul D.
Cliff, Jacqueline M.
机构：
[1] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England
[2] Univ Stellenbosch, Fac Hlth Sci, Dept Med Biochem, ZA-7505 Tygerberg, South Africa
来源：
JOURNAL OF INFECTIOUS DISEASES | 2007年 / 196卷 / 04期
关键词：
D O I：
10.1086/519746
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：649 / 650
页数：2
相关论文
共 50 条
  • [1] Biomarkers and surrogate end points in clinical trials of tuberculosis treatment
    Davies, Geraint Rhys
    Phillips, Patrick P. J.
    Nunn, Andrew J.
    JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (04): : 648 - 649
  • [2] Surrogate end points and their role in clinical trials: Reply from authors
    Kalikar, M. V.
    Thawani, V. R.
    Varadpande, U. K.
    Sontakke, S. D.
    Singh, R. P.
    Khiyani, R. K.
    INDIAN JOURNAL OF PHARMACOLOGY, 2009, 41 (01) : 55 - 55
  • [3] Esketamine clinical trials: reply to Maju et al.
    Gastaldon, C.
    Papola, D.
    Ostuzzi, G.
    Barbui, C.
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2020, 29
  • [4] Biomarkers as Surrogate End Points in Heart Failure Trials
    Felker, G. Michael
    HEART FAILURE CLINICS, 2011, 7 (04) : 501 - +
  • [5] A regulatory agency's perspective on the application of biomarkers and surrogate end points in clinical trials
    Henney, J
    BIOMARKERS AND SURROGATE ENDPOINTS: CLINICAL RESEARCH AND APPLICATIONS, 2000, 1205 : XIV - XVIII
  • [6] Surrogate End Points and Their Validation in Oncology Clinical Trials
    Zhao, Fengmin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (13) : 1436 - +
  • [7] Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues
    Skeen, Mark B.
    Pani, Luca
    JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2021, 38 (03) : 181 - 185
  • [8] Composite End Points in Clinical Trials Reply
    Tomlinson, George
    Detsky, Allan S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (17): : 1698 - 1698
  • [9] The Use of Modified Surrogate End Points in Cancer Clinical Trials
    Al Hadidi, Samer
    CANCER INVESTIGATION, 2022, 40 (01) : 14 - 16
  • [10] Surrogate end points for clinical trials of kidney disease progression
    Stevens, Lesley A.
    Greene, Tom
    Levey, Andrew S.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 1 (04): : 874 - 884
12345